Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Zotatifin · EFT-226

Small molecule · Inhibitor of eIF4A (EIF4A1) · developed by Effector Therapeutics

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Zotatifin?

Zotatifin (EFT-226) is a selective small-molecule inhibitor of eukaryotic translation initiation factor 4A (eIF4A). It binds eIF4A and enhances its interaction with mRNAs containing polypurine motifs in their 5'-UTR, repressing translation of oncogenes and survival factors including KRAS, MYC, MCL1, BCL2, and HER2. It is studied in oncology and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
EFT-226, Zota
Drug type
Small molecule
Targets
eIF4A (EIF4A1)
Mechanism
Inhibitor of eIF4A (EIF4A1)
Pathways
MAPK/ERK, PI3K/Akt, translation initiation, apoptosis
Therapy area
Infectious disease
Developer
Effector Therapeutics
In trials of
MEDP
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
2EWN8Z05CN

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04632381 Phase 1 Corona Virus Infection Completed MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Corona Virus Infection

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.